MONTREAL, Nov. 16, 2017 /CNW Telbec/ - In its efforts to fight opioid addiction, on Thursday, November 9, the Quebec government announced it will be offering free naloxone, an antidote to Fentanyl. Since the announcement, Omega Laboratories, a Montreal-based pharmaceutical firm specializing in injectable and non-injectable solutions, suddenly faced huge demand for that product. Omega Laboratories management therefore wishes to reiterate that it is currently deploying several measures to address this exceptional situation and to offer fair distribution to every drug store across Canada.
Demand for this product has grown 550% since the beginning of 2017. Despite this sudden spike in demand, Omega Laboratories is able to meet the demand of drug stores. The pharmaceutical company assures that it is in contact with all relevant stakeholders to account for the increased demand and avoid any possible delays in supply.
Given the scale of the current Fentanyl crisis across Canada, and anticipating a potential shortage, Omega Laboratories took preparatory steps to increase its production. Recently, the company even invested $40 million to adapt itself to increased demand for injectable products such as naloxone.
With the health of Canadians at the top of its priorities, Omega Laboratories is pleased to provide innovative solutions to mitigate the devastating consequences of the opioid crisis.
ABOUT OMEGA LABORATORIES LIMITED
Omega Laboratories Limited has been providing the Canadian medical community with a comprehensive line of innovative, specialized and leading-edge pharmaceutical products since 1958. The company's objective is to offer outstanding customer service and its employees are committed to meeting the challenge by completing their tasks with dedication and professionalism.
SOURCE Citoyen Optimum - Montréal
For further information: Jenna Dubé, Citoyen Optimum, Tel.: 581 996-3023, Email: firstname.lastname@example.org